Fundamental Global Inc. Reports First Quarter 2024 Financial Results
May 20, 2024 08:30 ET
|
Fundamental Global Inc.
Mooresville, NC, May 20, 2024 (GLOBE NEWSWIRE) -- Fundamental Global Inc. (Nasdaq: FGF, FGFPP) (the “Company” or "Fundamental Global"), formerly known as FG Financial Group, Inc. (“FG Financial”),...
Odysight.ai Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 16, 2024 08:30 ET
|
Odysight.ai Inc.
OMER, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (OTCQB: ODYS), a leading provider of visual based predictive maintenance (PdM) and condition-based monitoring (CBM) solutions,...
Eightco Announces First Quarter 2024 Financial Results
May 16, 2024 08:30 ET
|
Eightco Holdings Inc.
Quarter Driven by Capital Restructuring to Prioritize Financial Stability for Long-Term Revenue Growth. First quarter 2024 net income of $4.9mn versus net loss of $49.9mn for the prior year...
CEA Industries Inc. Reports First Quarter 2024 Results and Provides Update on Strategic Review Process
May 14, 2024 16:50 ET
|
CEA Industries Inc.
Louisville, Colorado, May 14, 2024 (GLOBE NEWSWIRE) -- CEA Industries Inc. (NASDAQ: CEAD, CEADW) (“CEA Industries” or the “Company”), is reporting results for the three months ended March 31, 2024. ...
BioRestorative Therapies Provides First Quarter 2024 Business Update
May 14, 2024 16:10 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based...
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
May 13, 2024 08:00 ET
|
Imunon, Inc.
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on...
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024 08:00 ET
|
GRI Bio, Inc.
Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) expected Q3 2024 and topline data on track for Q4 2024 ...
Research Frontiers Reports First Quarter 2024 Financial Results and Will Host a Conference Call at 5:30p.m. Today
May 09, 2024 16:01 ET
|
Research Frontiers Incorporated
WOODBURY, N.Y., May 09, 2024 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR) announced its financial results for its first quarter of 2024. Management will host a conference call today at...
Interpace Biosciences Announces First Quarter 2024 Financial and Business Results
May 09, 2024 16:01 ET
|
Interpace Biosciences, Inc.
●Q1 Revenue of $10.3 million; a 4% increase year-over-year ●Q1 Test volume up 10% year over year to record levels PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc....
NEXGEL to Report First Quarter 2024 Financial Results on May 13th
May 09, 2024 08:00 ET
|
NEXGEL, INC.
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider...